Role of albumin-bilirubin score in non-malignant liver disease  

作　　者：Shi-Xue Xu Fan Yang Nan Ge Jin-Tao Guo Si-Yu Sun 

机构地区：[1]Department of Gastroenterology,Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques,Shengjing Hospital of China Medical University,Shenyang 110004,Liaoning Province,China

出　　处：《World Journal of Gastroenterology》2024年第9期999-1004,共6页世界胃肠病学杂志（英文版）

摘　　要：The albumin-bilirubin(ALBI)score,which was proposed to assess the prognosis of patients with hepatocellular carcinoma,has gradually been extended to other liver diseases in recent years,including primary biliary cholangitis,liver cirrhosis,hepatitis,liver transplantation,and liver injury.The ALBI score is often compared with classical scores such as the Child-Pugh and model for end-stage liver disease scores or other noninvasive prediction models.It is widely employed because of its immunity to subjective evaluation indicators and ease of obtaining detection indicators.An increasing number of studies have confirmed that it is highly accurate for assessing the prognosis of patients with chronic liver disease;additionally,it has demonstrated good predictive performance for outcomes beyond survival in patients with liver diseases,such as decompensation events.This article presents a review of the application of ALBI scores in various non-malignant liver diseases.

关 键 词：Albumin-bilirubin score Liver cirrhosis Primary biliary cholangitis Hepatitis Liver transplantation Liver injury 

分 类 号：R575[医药卫生—消化系统]